|drug1534||Hydroxychloroquine Sulfate 400 mg twice a day Wiki||1.00|
|drug1536||Hydroxychloroquine Sulfate 600 mg twice a day Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.03|
There is one clinical trial.
The PATCH trial (Prevention And Treatment of COVID-19 with Hydroxychloroquine) is funded investigator-initiated trial that includes 3 cohorts. Cohort 1: a double-blind placebo controlled trial of high dose HCQ as a treatment for home bound COVID-19 positive patients; Cohort 2: a randomized study testing different doses of HCQ in hospitalized patients; Cohort 3: a double blind placebo controlled trial of low dose HCQ as a preventative medicine in health care workers.
Description: Cohort 1 (home quarantined COVID-19 patients): Median time to release from quarantine by meeting the following criteria: 1) No fever for 72 hours 2) improvement in other symptoms and 3) 7 or 10 days (depending on CDC guidance at the time) have elapsed since the beginning of symptom onset.Measure: Time to Release From Quarantine Time Time: until quarantine release or hospitalization
Description: Cohort 2 (hospitalized COVID-19 patients): median number of days until hospital dischargeMeasure: Time to Hospital Discharge Time: until hospital discharge
Description: Cohort 3 Physicians and nurse prophylaxis: Rate of COVID-19 infection at 2 monthsMeasure: Number of Health Care Workers Who Developed SARS-COV-2 Infection Time: 2 months
Description: Cohort 1 rate of participant-reported secondary infection of housematesMeasure: Rate of Housemate Infection Time: until quarantine release, or approximately <20 days
Description: Cohort 1 rate of hospitalizationMeasure: Rate of Hospitalization Time: until quarantine release
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports